CARB-X announced Tuesday an award of up to $3.6 million (plus up to $10.2 million in milestones) to Maryland-based Novel Microdevices to develop a rapid, point-of-care, battery-powered diagnostic for sexually transmitted infections such as chlamydia and gonorrhea.

The test—which will also identify antibiotic resistance—will diagnose infections in about 25 minutes from a vaginal swab or urine sample and require no sample preparation, making it “particularly suited” for LMICs, according…

The Danish health ministry’s Statens Serum Institut (SSI) announced this week that its candidate recombinant protein subunit vaccine proved safe and induced protective antibodies in all vaccinated subjects in the first-ever Phase 1 trial of a chlamydia shot.

Thirty-five healthy women received three adjuvanted intramuscular injections or placebo at 0, 1, and 4 months followed by two intranasal unadjuvanted boosts or placebo (one in each nostril) at 4.5 and 5 months.